Lymphoma (includes NHL, HL, CNS Lymphoma)
(ASCO in Action) Aug 8, 2018 - On Aug. 8, 2018, the Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo, Kyowa Kirin, Inc.) for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
The approval of mogamulizumab-kpkc, a CC chemokine...
(Genetic Engineering & Biotechnology News) Aug 2, 2018 - Epizyme said today it will halt a Phase II clinical trial assessing its lead candidate, the cancer treatment tazemetostat in relapsed and/or refractory diffuse large B-cell lymphoma (r/r DLBCL).
The trial halt comes more than three months after the FDA imposed a partial...
There are no Lymphoma (includes NHL, HL, CNS Lymphoma) OBR Green articles.